Patients were randomly assigned to once-weekly exenatide or once-daily glargine to be given in addition to their existing oral glucose-lowering regimens. Randomisation was by computer-generated random sequence with an interactive voice-response system. One-to-one allocation and block size four were used, stratiÔ¨Å  ed by country and concomitant oral glucose-lowering therapy (70% of patients taking metformin only, 30% taking metformin plus sulfonylureas). Patients, investigators, and data analysts were not masked to treatment assignment. Procedures Patients assigned to exenatide received 2 mg subcutaneous injections once weekly from randomisation. Glargine dose was established by the Initiate Insulin by Aggressive Titration and Education (INITIATE) algorithm, 10 with